Koyfin Home > Directory > Health Care > Revance Therapeutics > EBITDA / Interest Expenses

Revance Therapeutics EBITDA / Interest Expenses Chart (RVNC)

Revance Therapeutics annual/quarterly EBITDA / Interest Expenses from 2012 to 2020. EBITDA / Interest is the interest coverage ratio and measures the ability of a company to service its debt.
  • Revance Therapeutics EBITDA / Interest Expenses for the quarter ending June 06, 2020 was $-13m a -14,123.89% increase of 1,792m year over year
  • Revance Therapeutics EBITDA / Interest Expenses for the last 12 months ending June 06, 2020 was $-31m a -7,021.04% increase of 2,154m year over year
  • Revance Therapeutics Annual EBITDA / Interest Expenses for 2018 was $-3,202m a 92.07% decrease of -2,949m from 2017
  • Revance Therapeutics Annual EBITDA / Interest Expenses for 2017 was $-254m a 71.71% decrease of -182m from 2016
  • Revance Therapeutics Annual EBITDA / Interest Expenses for 2016 was $-72m a 17.72% decrease of -13m from 2015
Other Ratios Metrics:
  • Revance Therapeutics Total Debt / Capital for the quarter ending March 03, 2018 was $0m a -426.67% decrease of -2m year over year
  • Revance Therapeutics Other Liabilities for the quarter ending September 09, 2018 was $19m a 68.91% increase of 13m year over year
  • Revance Therapeutics Total Debt / Equity for the quarter ending March 03, 2018 was $0m a -436.21% decrease of -2m year over year
View Chart On Koyfin

Quarterly RVNC EBITDA / Interest Expenses Data

06/2020$-13m
03/2020$-27m
03/2018$-802m
12/2017$-1,805m
09/2017$-292m
06/2017$-188m
03/2017$-139m
12/2016$-85m
09/2016$-68m
06/2016$-76m

Annual RVNC EBITDA / Interest Expenses Data

2018$-3,202m
2017$-254m
2016$-72m
2015$-59m
2014$-5m
2013$-2m
2012$-1m
2011$-1m